Financials NeuBase Therapeutics, Inc. Nasdaq
Equities
NBSE
US64132K2015
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.378 USD | -3.20% | 0.00% | -48.93% |
Valuation
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Capitalization 1 | 88.56 | 172.1 | 118.1 | 11.82 | 1.379 |
Enterprise Value (EV) 1 | 88.56 | 172.1 | 118.1 | 11.82 | 1.379 |
P/E ratio | - | - | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | -26,830,918 x | - | - | - | - |
FCF Yield | -0% | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 854 | 1,156 | 1,636 | 1,613 | 3,752 |
Reference price 2 | 95.20 | 127.0 | 62.40 | 7.480 | 0.3406 |
Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -26.34 | -17.07 | -26.57 | -33.32 | -14.01 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -26.96 | -17.38 | -25.41 | -33.78 | -12.32 |
Net income 1 | -26.96 | -17.38 | -25.41 | -33.78 | -12.32 |
Net margin | - | - | - | - | - |
EPS | - | - | - | - | - |
Free Cash Flow | -3.301 | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: September | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -5.9 | -8.839 | -7.169 | -7.305 | -9.929 | -8.361 | -7.723 | - | -4.164 | -3.688 | -2.813 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -5.522 | -8.663 | -7.158 | -7.729 | -9.924 | -8.492 | -7.632 | -4.369 | -4.093 | -3.447 | -1.821 |
Net income 1 | -5.5 | -8.663 | -7.158 | -7.729 | -9.924 | -8.492 | -7.632 | -4.369 | -4.093 | -3.447 | -1.821 |
Net margin | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 5/13/21 | 8/13/21 | 12/23/21 | 2/11/22 | 5/12/22 | 8/11/22 | 12/21/22 | 2/14/23 | 5/11/23 | 8/14/23 | 11/9/23 |
Balance Sheet Analysis
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | -3.3 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | 0.46 | - | - | - | 1.2 |
Capex / Sales | - | - | - | - | - |
Announcement Date | 1/9/20 | 12/23/20 | 12/23/21 | 12/21/22 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+47.58% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- O7P Stock
- NBSE Stock
- Financials NeuBase Therapeutics, Inc.